Exploratory Study of Switching From Combustible Cigarettes to the BIDI E-cigarette

Smoking Cessation Clinical Trial

Official title:

Exploratory Study of Switching From Combustible Cigarettes to the BIDI E-cigarette

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05855343
• Other study ID #: BIDI
• Status: Completed
• Phase: N/A
• Start date: February 14, 2023
• Est. completion date: December 5, 2023

Study information

• Verified date: March 2024
• Source: Rose Research Center, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to shed light on the importance of nicotine pharmacokinetics in switching to a reduced-harm product by fully matching the nicotine pharmacokinetics of smokers' usual brands of cigarettes.

The primary objective is to ascertain the degree of smoking reduction when smokers attempt to switch to an e-cigarette that matches peak nicotine concentrations of a cigarette.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: December 5, 2023
• Est. primary completion date: September 5, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 22 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Has signed the ICF and is able to understand the information provided in the ICF.

2. Is 22 to 65 years of age (inclusive) at screening.

3. Smokes = 10 commercially available CCs per day (no brand restrictions), for the last 12 months.

4. Expired air CO reading of at least 10 ppm as assessed at the screening session.

5. Interested in switching to an electronic cigarette.

6. Willing and able to comply with the requirements of the study.

7. Owns a smart phone with text message and data capabilities compatible with necessary surveys.

Exclusion Criteria:

1. Is unhealthy or cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason) as judged by the Investigator or designated medical staff based on all available assessments from the screening period (e.g., vital signs, physical examination, ECG, concomitant medications and medical history).

2. PHQ-9 score greater than 9, or a score greater than 0 on item #9 ("Thoughts that you would be better off dead, or of hurting yourself in some way") at screening.

3. Planned use of an FDA-approved smoking cessation product during the study.

4. High Blood Pressure (systolic >150 mm Hg, diastolic >95 mm Hg) at screening.

5. Body mass index (BMI) less than 15.0 kg/m2 or greater than 40.0 kg/m2 at screening.

6. Coronary heart disease, structural cardiac disease (including, but not limited to valvular heart disease or cardiac murmurs), cardiac dysrhythmias, syncope, cardiac chest pain, or history of heart attack or heart failure.

7. Has received psychotherapy or behavioral treatments within 30 days of screening, or during the study.

8. Taking antidepressants or psychoactive medications (e.g. antipsychotics, benzodiazepines, hypnotics).

9. Use of any of these products in the past 30 days:

1. Illegal drugs (or if the urine drug screen is positive for cocaine, THC, amphetamines, phencyclidine (PCP), or opiates without a medical prescription);

2. Experimental (investigational) drugs that are unknown to participant;

3. Chronic opiate use.

10. Use of smokeless tobacco (chewing tobacco, snuff), cigars (except for "Black & Mild" cigars or Cigarillos), pipes, hookah, e-cigarettes, nicotine replacement therapy or other smoking cessation treatments within 14 days of screening.

11. Pregnant or nursing (by self-report) or positive pregnancy test.

12. Enrollment is complete.

Related Conditions & MeSH terms

• Smoking Cessation

Intervention

Other:
• BIDI Stick e-cigarette
The BIDI will be dispensed, and subjects will be instructed to use the BIDI as often as they like during the 12 week period, and to switch completely to the BIDI within 1 week. If, however, they do smoke any CC, they will also be instructed to use the BIDI immediately before each CC to relieve their craving as much as possible before smoking their usual brand. The BIDI will also be the first product that they are instructed to use each morning. Smokers will be told to try to completely substitute BIDI for CCs by the end of the first week of use.

Locations

Country	Name	City	State
United States	Rose Research Center	Charlotte	North Carolina
United States	Rose Research Center	Raleigh	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Rose Research Center, LLC	Foundation for a Smoke Free World INC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of participants that completely switch from combustible cigarettes to e-cigarette	Self-report of no smoking	Daily during Week 9 - Week 12
Other	Number of participants that completely switch from combustible cigarettes to e-cigarette	Expired air carbon monoxide (CO) value of <5 ppm	Week 9 - Week 12
Other	Number of participants that completely switch from combustible cigarettes to e-cigarette	Expired air carbon monoxide (CO) value of <5 ppm	Week 12
Other	Number of participants that completely switch from combustible cigarettes to e-cigarette	Self-report of no smoking	Week 12
Primary	Degree of Smoking Reduction	Change in expired air carbon monoxide (CO) at the end of the product use period	After 12 Weeks
Primary	Degree of Smoking Reduction	Change in self-reported cigarettes smoked daily	From Baseline to Week 12
Secondary	Subjective response to an e-cigarette	To assess subjective satisfaction and other perceived rewarding or aversive effects accompanying e-cigarette use and combustible cigarette use using the modified (e-Cigarette) Cigarette Evaluation Questionnaire. This questionnaire contains five subscale scores: smoking satisfaction (satisfying, tastes good, enjoy smoking), psychological rewards (calms down, more awake, less irritable, helps concentrate, reduces hunger), aversion (dizziness, nauseated), enjoyment of respiratory tract sensations (single-item assessment), craving reduction (single-item assessment). Participants will be asked to assess the 12 items of the questionnaire on a 7-point scale, ranging from "not at all" to "extremely".	From Baseline to Week 12